BBK Worldwide Raises Growth Capital

BBK Worldwide Raises Growth Capital

Investment to Accelerate Global Expansion, Support Company's Continued Innovation and Acquisition Strategy

BOSTON, MA--(Marketwired - September 15, 2014) - Fueled by industry demand for the company's expertise in complex clinical trials and studies of rare diseases, BBK Worldwide, the flagship company of BBK Holdings, LLC, has secured more than $3 million in financing. The investment was led by a private investor with additional support from the company's Founding Principals, Joan F. Bachenheimer and Bonnie A. Brescia.

In the past year, 23 of the world's top 25 pharmaceutical companies have relied on BBK to ensure that the right patients are enrolled for key clinical studies all over the world, many for incredibly complex trials or in studies of rare diseases. In addition, BBK's patient recruitment platform, TrialCentralNet℠, and proven advertising strategies have supported studies for half of the world's top 20 selling drugs -- a combined 65 billion dollar market in 2013 for the developers of those new therapies.

BBK will use the new investment to expand its clinical technology suite -- through in-house development and acquisition -- including its patient recruitment platform, TrialCentralNet℠, and mobile app platform for patient and site engagement, My Clinical Study Buddy℠. Built from the ground up to empower global clinical research study teams with the data they need when they need it, TrialCentralNet℠ powers BBK's adaptive recruitment approach -- a data-centric model designed to remove silos and foster study team collaboration, enabling informed decisions at critical study milestones and the ability to respond more rapidly to previously unforeseen enrollment challenges.

"The global operating environment for clinical trials has become more complex and challenging and, as a result, demand for new approaches and new solutions to improve patient enrollment has increased dramatically," said Ken Getz, director of Sponsored Research Programs for the Center for the Study of Drug Development at Tufts University School of Medicine. "BBK has been pushing technological change to innovate and to engage study volunteers in clinical research."

To accommodate its growing team, BBK moved to a custom 15,000-square foot headquarters in Needham, Mass. in June of last year. The company expects to increase its staff by more than 10 percent by the end of the year.

"We know from having managed thousands of studies worldwide that success is dependent on a mix of technologies, data analysis and strategic branding and advertising, and we're thrilled by the overwhelmingly positive response to our new adaptive model," said Bachenheimer. "This growth capital will allow us to continue to deliver the kinds of game-changing technologies and sophisticated recruitment and engagement strategies that our clients need to reduce enrollment costs and timelines."

"Interest in the TrialCentralNet℠ platform is at an all-time high as our clients look to drive study efficiencies and further clinical development," said Brescia. "Our deep global expertise and alliances combined with our innovations in emerging technologies like mobile allow us to deliver the kinds of campaigns needed to enroll studies today, and continues to be a core competitive advantage. This latest investment further enables us to help our clients improve patient enrollment performance and execution -- and in the end, help bring new therapies and medicines to the people who need them."

Tweet this: .@BBKWorldwide raises more than $3M to support #patientrecruitment #clinicaltrials #data leadership

About BBK Worldwide
With more than three decades of experience across a wide variety of therapies and medicines, BBK Worldwide is the global leader in patient recruitment for the clinical trial industry. BBK's latest innovation is the introduction of adaptive recruitment -- a new specialty in clinical trial marketing proven to protect global enrollment integrity, specifically within a changing or threatened landscape. BBK is a privately held, women owned business, headquartered in Needham, Mass. For more information, visit:

Image Available:

Contact Information


    Juli Greenwood
    BBK Worldwide
    [email protected]
    mobile: 617-515-8412
    office: 617-630-5546  


BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.